Pricing Log in Create free account
Saturday 17 October 2026 Export SRPT’s income statement to Excel — free account

Sarepta Therapeutics, Inc.

SRPT Healthcare Biotechnology

Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

17.06 0.73 −4.10%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
4.4×
Dividend yield
—
F-score
3/9
Altman Z
−0.97
Beneish M
−3.41
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Sarepta Therapeutics, Inc. (SRPT) Business Profile

Updated before January 2025

Company Overview

Sarepta Therapeutics, Inc. (SRPT) is a leading biotechnology company headquartered in Cambridge, Massachusetts, USA. Founded in 1980 as AntiVirals Inc., the company underwent a rebranding in 2012 to become Sarepta Therapeutics, reflecting its focus on developing precision genetic medicine. Sarepta specializes in the research, development, and commercialization of therapies for rare diseases, particularly those caused by genetic mutations. The company is best known for its pioneering work in the treatment of Duchenne muscular dystrophy (DMD), a rare and debilitating genetic disorder.

Sarepta’s leadership team is composed of experienced professionals in the biotechnology and pharmaceutical industries. As of 2023, the company is led by CEO Doug Ingram, who has been instrumental in driving Sarepta’s strategic vision and expanding its portfolio of genetic therapies. The company’s board of directors and executive team include experts in genetic medicine, regulatory affairs, and commercial strategy, ensuring a strong foundation for innovation and growth.

Core Business Segments

Sarepta Therapeutics operates primarily in the field of genetic medicine, with a focus on rare diseases. Its core business segments include:

1. RNA-Based Therapies

Sarepta has developed a suite of RNA-based therapies aimed at treating Duchenne muscular dystrophy (DMD). These therapies use exon-skipping technology to address specific genetic mutations that cause the disease. Key products in this category include:

  • Exondys 51 (eteplirsen): Approved by the FDA in 2016, this was the first RNA-based therapy for DMD. It targets exon 51 skipping.
  • Vyondys 53 (golodirsen): Approved in 2019, this therapy targets exon 53 skipping.
  • Amondys 45 (casimersen): Approved in 2021, this therapy targets exon 45 skipping.

2. Gene Therapy

Sarepta is at the forefront of gene therapy development, focusing on delivering functional copies of defective genes to treat genetic disorders. The company’s gene therapy pipeline includes:

  • SRP-9001 (delandistrogene moxeparvovec): A gene therapy candidate for DMD that delivers micro-dystrophin, a shortened but functional version of the dystrophin protein.
  • Other Gene Therapy Programs: Sarepta is also exploring gene therapies for limb-girdle muscular dystrophy (LGMD) and other rare diseases.

3. Research and Development (R&D)

Sarepta invests heavily in R&D to expand its pipeline of genetic therapies. The company collaborates with academic institutions, research organizations, and other biotech firms to advance its scientific capabilities. Its R&D efforts focus on:

  • Developing next-generation RNA and gene therapies.
  • Exploring new therapeutic areas beyond DMD and LGMD.
  • Enhancing delivery mechanisms for genetic medicines.

Business Model

Sarepta Therapeutics operates on a business model centered around innovation, collaboration, and commercialization. The company generates revenue primarily through the sale of its FDA-approved therapies for DMD. Its business model includes:

  • Product Sales: Sarepta’s approved therapies, such as Exondys 51, Vyondys 53, and Amondys 45, contribute significantly to its revenue.
  • Collaborations and Partnerships: Sarepta partners with academic institutions, research organizations, and other biotech companies to co-develop therapies and share resources.
  • Licensing Agreements: The company licenses its technologies and intellectual property to other organizations, generating additional revenue streams.
  • Pipeline Expansion: Sarepta continuously invests in R&D to expand its pipeline, ensuring a steady flow of innovative therapies.

Strategic Direction

Sarepta Therapeutics has a clear strategic vision aimed at maintaining its leadership in genetic medicine. Key elements of its strategic direction include:

  • Pipeline Expansion: Sarepta is committed to advancing its pipeline of RNA-based and gene therapies. The company is exploring new therapeutic areas, including central nervous system (CNS) disorders and metabolic diseases.
  • Global Expansion: Sarepta aims to expand its presence in international markets, particularly in Europe and Asia, to make its therapies accessible to a broader patient population.
  • Sustainability Goals: The company is focused on sustainable manufacturing practices and reducing its environmental footprint. Sarepta is also committed to ethical clinical trials and patient-centric approaches.
  • Innovation in Delivery Mechanisms: Sarepta is investing in advanced delivery technologies to improve the efficacy and safety of its genetic therapies.

Competitive Landscape

Sarepta Therapeutics operates in a highly competitive biotechnology sector. Key competitors include:

  • Pfizer Inc.: Pfizer is developing gene therapies for DMD and other rare diseases, posing direct competition to Sarepta’s pipeline.
  • Solid Biosciences: This company focuses on gene therapies for DMD and has a pipeline that overlaps with Sarepta’s offerings.
  • BioMarin Pharmaceutical Inc.: BioMarin specializes in therapies for rare genetic disorders and competes with Sarepta in the gene therapy space.
  • Wave Life Sciences: Wave is developing RNA-based therapies for genetic diseases, including DMD.

Despite the competition, Sarepta’s extensive pipeline and first-mover advantage in RNA-based therapies provide it with a competitive edge.

Risk Factors

Sarepta Therapeutics faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The approval process for genetic therapies is complex and uncertain. Delays or rejections by regulatory authorities could affect Sarepta’s product launches.
  • Market Dependence: Sarepta relies heavily on its DMD therapies for revenue. Any decline in sales or competition could impact its financial stability.
  • Supply Chain Disruptions: The company depends on specialized suppliers for raw materials and manufacturing. Disruptions in the supply chain could delay production.
  • R&D Risks: High R&D costs and the uncertainty of clinical trial outcomes pose significant risks.
  • Competition: Intense competition from other biotech firms could erode Sarepta’s market share.

Recent Developments

Sarepta Therapeutics has made significant strides in recent years. Key developments include:

  • FDA Approval of Amondys 45: The approval of Amondys 45 in 2021 expanded Sarepta’s portfolio of DMD therapies.
  • Advancements in Gene Therapy: Sarepta’s SRP-9001 gene therapy candidate has shown promising results in clinical trials, bringing it closer to potential FDA approval.
  • Partnerships: Sarepta has entered into strategic partnerships with companies like Roche to co-develop and commercialize its gene therapies.
  • Global Developments: The COVID-19 pandemic posed challenges but also highlighted the importance of genetic medicine, boosting interest in Sarepta’s therapies.

Investment Considerations

Investors considering Sarepta Therapeutics should weigh the following factors:

Strengths

  • Leadership in Genetic Medicine: Sarepta is a pioneer in RNA-based and gene therapies, with a strong pipeline and first-mover advantage.
  • Growing Market: The market for genetic therapies is expanding, providing growth opportunities for Sarepta.
  • Strategic Partnerships: Collaborations with industry leaders enhance Sarepta’s R&D capabilities and market reach.

Risks

  • High R&D Costs: Sarepta’s heavy investment in R&D could strain its financial resources.
  • Regulatory Uncertainty: The approval process for genetic therapies is unpredictable and could delay product launches.
  • Market Dependence: Reliance on DMD therapies makes Sarepta vulnerable to market fluctuations.

Conclusion

Sarepta Therapeutics, Inc. is a leader in the field of genetic medicine, with a strong focus on rare diseases like Duchenne muscular dystrophy. The company’s innovative therapies, robust pipeline, and strategic partnerships position it for long-term growth. However, investors should consider the risks associated with regulatory challenges, market dependence, and competition. With its commitment to innovation and patient-centric approaches, Sarepta is well-positioned to maintain its leadership in the biotechnology sector and drive future growth.